ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-13 16:57:39,2023-10-13T16:57:39-04:00,2023-10-13,7 Dividend Kings to Buy for Royal Returns,"Of the 500 stocks listed in the benchmark S&P 500 index, only 51 (10%) are considered dividend kings and have increased their dividend payout to stockholders for 50 consecutive years or longer. Dividend kings are often stocks of long-established blue-chip companies that have prioritized returning capital to their shareholders through consistent dividend payments.",investorplace.com,https://investorplace.com/2023/10/7-dividend-kings-to-buy-for-royal-returns/,https://images.financialmodelingprep.com/news/7-dividend-kings-to-buy-for-royal-returns-20231013.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-13 08:16:13,2023-10-13T08:16:13-04:00,2023-10-13,AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study,AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.,zacks.com,https://www.zacks.com/stock/news/2165416/abbvie-s-abbv-rinvoq-meets-key-goal-in-phase-ii-vitiligo-study,https://images.financialmodelingprep.com/news/abbvies-abbv-rinvoq-meets-key-goal-in-phase-ii-20231013.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-14 06:52:00,2023-10-14T06:52:00-04:00,2023-10-14,3 Dividend Growth Stocks You Can Buy and Hold Forever,"AbbVie boasts a stellar dividend track record and a resilient business. Eli Lilly's dividend yield might be low, but there's a lot more to the story.",fool.com,https://www.fool.com/investing/2023/10/14/3-dividend-growth-stocks-you-can-buy-and-hold-fore/,https://images.financialmodelingprep.com/news/3-dividend-growth-stocks-you-can-buy-and-hold-forever-20231014.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-15 11:15:00,2023-10-15T11:15:00-04:00,2023-10-15,AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints,"SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs1 Risankizumab met both primary endpoints of non-inferiority for clinical remissiona (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remissionb at week 48 versus ustekinumab1 Risankizumab showed superiority versus ustekinumab for all ranked secondary endpoints, including achievement of clinical remissiona at week 48, achievement of endoscopic responsec at week 48 and 24, achievement of steroid-free endoscopic remissiond at week 48 and achievement of steroid-free clinical remissione at week 481 Safety results were consistent with the overall safety profile of risankizumab, with no new safety risks identified NORTH CHICAGO, Ill. , Oct. 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (SKYRIZI®, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA®, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.1 The data were presented at the United European Gastroenterology (UEG) Week 2023, October 14-17.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvies-skyrizi-risankizumab-versus-stelara-ustekinumab-head-to-head-study-in-crohns-disease-meets-all-primary-and-secondary-endpoints-301956749.html,https://images.financialmodelingprep.com/news/abbvies-skyrizi-risankizumab-versus-stelara-ustekinumab-headtohead-study-in-20231015.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-16 18:47:07,2023-10-16T18:47:07-04:00,2023-10-16,AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why,"AbbVie (ABBV) concluded the recent trading session at $147.23, signifying a -0.49% move from its prior day's close.",zacks.com,https://www.zacks.com/stock/news/2166732/abbvie-abbv-stock-sinks-as-market-gains-here-s-why,https://images.financialmodelingprep.com/news/abbvie-abbv-stock-sinks-as-market-gains-heres-why-20231016.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-16 10:44:28,2023-10-16T10:44:28-04:00,2023-10-16,AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014,"Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its parent company and the S&P 500, thanks to the success of Humira. In 2022, AbbVie became the second-largest pharmaceutical company, but despite diversifying into other areas, the impact of Humira's patent cliff in 2023 is affecting its growth. Despite declining Humira sales, AbbVie remains resilient, focusing on new therapies, M&A, and R&D for sustained growth.",seekingalpha.com,https://seekingalpha.com/article/4641021-abbvie-successfully-navigating-humira-patent-cliff-with-4-percent-yield-and-270-percent-dgr-since-2014,https://images.financialmodelingprep.com/news/abbvie-successfully-navigating-humiras-patent-cliff-with-4-yield-20231016.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-17 13:58:45,2023-10-17T13:58:45-04:00,2023-10-17,AbbVie: Q2 Success Sets The Stage For Consistent Growth,"AbbVie is a leading pharmaceutical company with a strong history and a diverse portfolio of products. The company's flagship product, Humira, has generated significant revenue and it has a pipeline of promising treatments for various diseases. AbbVie's financials show consistent growth and its valuation suggests potential for future value growth.",seekingalpha.com,https://seekingalpha.com/article/4641341-abbvie-q2-success-sets-the-stage-for-consistent-growth,https://images.financialmodelingprep.com/news/abbvie-q2-success-sets-the-stage-for-consistent-growth-20231017.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-17 11:32:27,2023-10-17T11:32:27-04:00,2023-10-17,3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off,AbbVie is a high-yield dividend stock that packs a punch. Stryker is a well-rounded business.,fool.com,https://www.fool.com/investing/2023/10/17/supercharged-dividend-stocks-buy-market-sell-off/,https://images.financialmodelingprep.com/news/3-supercharged-dividend-stocks-to-buy-if-theres-a-20231017.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-17 09:20:17,2023-10-17T09:20:17-04:00,2023-10-17,AbbVie: Why You Should Pay Attention To This High-Yielding Dividend King (Rating Downgrade),"Dividend Kings are the most battle-tested dividend payers on Wall Street, with AbbVie being just one of four in the healthcare sector. The pharmaceutical's 4% dividend yield is covered by both earnings and free cash flow and is substantially higher than the 1.6% yield of the S&P 500 index. AbbVie's portfolio of medicines and its pipeline could catalyze a post-Humira rebound.",seekingalpha.com,https://seekingalpha.com/article/4641259-abbvie-why-you-should-pay-attention-to-this-high-yielding-dividend-king-rating-downgrade,https://images.financialmodelingprep.com/news/abbvie-why-you-should-pay-attention-to-this-highyielding-20231017.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-18 11:00:00,2023-10-18T11:00:00-04:00,2023-10-18,AbbVie: The Humira Loss May Be Fully Priced In After All,"The US FDA has already approved two directly interchangeable biosimilars to ABBV's Humira, namely Boehringer Ingelheim's Cyltezo and PFE's ABRILADA. The impact on ABBV's sales may be great, since its competitors have priced their biosimilars at notable discounts, with the third interchangeable biosimilar likely to be approved sooner rather than later. Even so, the stock has maintained much of its gains since December 2021, since the Humira patent expiry was well known for years and pessimism was largely priced in.",seekingalpha.com,https://seekingalpha.com/article/4641497-abbvie-the-humira-loss-may-be-fully-priced-in-after-all,https://images.financialmodelingprep.com/news/abbvie-the-humira-loss-may-be-fully-priced-in-20231018.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-18 10:31:57,2023-10-18T10:31:57-04:00,2023-10-18,AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2167845/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-is-attracting-investor-attention-here-is-20231018.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-18 08:15:00,2023-10-18T08:15:00-04:00,2023-10-18,My Dividend Stock Portfolio: New September Dividend Record - 98 Holdings With 22 Buys,My Dividend Stock Portfolio: New September Dividend Record - 98 Holdings With 22 Buys,seekingalpha.com,https://seekingalpha.com/article/4641388-my-dividend-stock-portfolio-new-september-dividend-record-98-holdings-with-22-buys,https://images.financialmodelingprep.com/news/my-dividend-stock-portfolio-new-september-dividend-record-98-20231018.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-19 09:15:31,2023-10-19T09:15:31-04:00,2023-10-19,7 Dividend Aristocrats to Batten Down the Hatches,"With market uncertainty practically being the only form of certainty available, investors should consider dividend aristocrats. By definition, companies under this category belong in the S&P 500 index which consistently raises their dividends for at least the past 25 years.",investorplace.com,https://investorplace.com/2023/10/7-dividend-aristocrats-to-batten-down-the-hatches/,https://images.financialmodelingprep.com/news/7-dividend-aristocrats-to-batten-down-the-hatches-20231019.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-19 07:05:00,2023-10-19T07:05:00-04:00,2023-10-19,Is AbbVie Stock Too Pricey to Touch Right Now?,"AbbVie's valuation is elevated, though it has no major catalysts coming up. It's also seeing sales of its biggest-earning medicine erode rapidly.",fool.com,https://www.fool.com/investing/2023/10/19/is-abbvie-stock-too-pricey-to-touch-right-now/,https://images.financialmodelingprep.com/news/is-abbvie-stock-too-pricey-to-touch-right-now-20231019.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-20 11:17:32,2023-10-20T11:17:32-04:00,2023-10-20,Earnings Preview: AbbVie (ABBV) Q3 Earnings Expected to Decline,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2169676/earnings-preview-abbvie-abbv-q3-earnings-expected-to-decline,https://images.financialmodelingprep.com/news/earnings-preview-abbvie-abbv-q3-earnings-expected-to-decline-20231020.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-20 06:45:17,2023-10-20T06:45:17-04:00,2023-10-20,7 Dividend Stocks to Buy and Hold Forever and Ever,"Recently, investors searching for dividend stocks to buy have seen more opportunity. Some looking for income over a longer term horizon have flooded into the bond market.",investorplace.com,https://investorplace.com/2023/10/7-dividend-stocks-to-buy-and-hold-forever-and-ever/,https://images.financialmodelingprep.com/news/7-dividend-stocks-to-buy-and-hold-forever-and-20231020.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-23 18:47:31,2023-10-23T18:47:31-04:00,2023-10-23,AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know,"In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day.",zacks.com,https://www.zacks.com/stock/news/2170454/abbvie-abbv-sees-a-more-significant-dip-than-broader-market-some-facts-to-know,https://images.financialmodelingprep.com/news/abbvie-abbv-sees-a-more-significant-dip-than-broader-20231023.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-24 10:32:27,2023-10-24T10:32:27-04:00,2023-10-24,3 Biotech Stocks With Decent Dividend for a Steady Return,"Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.",zacks.com,https://www.zacks.com/stock/news/2170733/3-biotech-stocks-with-decent-dividend-for-a-steady-return,https://images.financialmodelingprep.com/news/3-biotech-stocks-with-decent-dividend-for-a-steady-20231024.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-24 08:30:00,2023-10-24T08:30:00-04:00,2023-10-24,Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines,–All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508). – Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and short duration of effect within 2-3 weeks.,prnewswire.com,https://www.prnewswire.com/news-releases/allergan-aesthetics-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-trenibotulinumtoxine-bonte-for-the-treatment-of-glabellar-lines-301965107.html,https://images.financialmodelingprep.com/news/allergan-aesthetics-announces-positive-topline-results-from-two-pivotal-20231024.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-25 13:32:15,2023-10-25T13:32:15-04:00,2023-10-25,Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again,AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,zacks.com,https://www.zacks.com/stock/news/2171920/why-abbvie-abbv-is-poised-to-beat-earnings-estimates-again,https://images.financialmodelingprep.com/news/why-abbvie-abbv-is-poised-to-beat-earnings-estimates-20231025.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-25 11:42:36,2023-10-25T11:42:36-04:00,2023-10-25,"Earnings Previews for AbbVie, Chevron, Exxon Mobil; All Reporting Friday Morning","Before U.S. markets open on Thursday, the U.S. Bureau of Economic Analysis will release its first estimate of third-quarter gross domestic product (GDP).",247wallst.com,https://247wallst.com/investing/2023/10/25/earnings-previews-for-abbvie-chevron-exxon-mobil-all-reporting-friday-morning/,https://images.financialmodelingprep.com/news/earnings-previews-for-abbvie-chevron-exxon-mobil-all-reporting-20231025.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-25 06:15:00,2023-10-25T06:15:00-04:00,2023-10-25,The 7 Best Forever Stocks to Buy for October 2023,"Navigating the thunderstorm of fluctuating markets, savvy investors anchor their portfolios with the best forever stocks. These stocks have proven resilient in the face of economic uncertainties and continue to flourish amid influential megatrends.",investorplace.com,https://investorplace.com/2023/10/the-7-best-forever-stocks-to-buy-for-october-2023/,https://images.financialmodelingprep.com/news/the-7-best-forever-stocks-to-buy-for-october-2023-20231025.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-26 12:02:19,2023-10-26T12:02:19-04:00,2023-10-26,Why Earnings Season Could Be Great for AbbVie (ABBV),AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,zacks.com,https://www.zacks.com/stock/news/2172934/why-earnings-season-could-be-great-for-abbvie-abbv,https://images.financialmodelingprep.com/news/why-earnings-season-could-be-great-for-abbvie-abbv-20231026.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-26 07:50:00,2023-10-26T07:50:00-04:00,2023-10-26,"Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond","AbbVie has good reasons for investors to take a close look at the stock, even though its best-selling drug recently lost patent exclusivity. Tandem Diabetes Care has plenty of room to increase sales, despite the macroeconomic challenges that have hindered it recently.",fool.com,https://www.fool.com/investing/2023/10/26/got-1000-these-2-stocks-could-be-bargain-buys-for/,https://images.financialmodelingprep.com/news/got-1000-these-2-stocks-could-be-bargain-buys-20231026.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 15:06:17,2023-10-27T15:06:17-04:00,2023-10-27,Why AbbVie Stock Fell Today,"AbbVie stock fell today despite easily exceeding estimates for its third quarter. Revenue declines across AbbVie's immunology, oncology, and aesthetics portfolios were partially offset by strong growth from newer neuroscience drugs.",fool.com,https://www.fool.com/investing/2023/10/27/why-abbvie-stock-fell-today/,https://images.financialmodelingprep.com/news/why-abbvie-stock-fell-today-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 13:34:03,2023-10-27T13:34:03-04:00,2023-10-27,AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript,"AbbVie Inc. (NYSE:ABBV ) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Rob Michael - President & Chief Operating Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics Tom Hudson - Senior Vice President, R&D & Chief Scientific Officer Scott Reents - Executive Vice President & Chief Financer Roopal Thakkar - SVP, Development & Regulatory Affairs & Chief Medical Officer Conference Call Participants Chris Shibutani - Goldman Sachs Mohit Bansal - Wells Fargo Christopher Schott - JPMorgan Terence Flynn - Morgan Stanley Alice Nettleton - Wolfe Research Vamil Divan - Guggenheim Securities Steve Scala - TD Cowen Gary Nachman - Raymond James Luisa Hector - Berenberg David Risinger - Leerink Partners Geoff Meacham - BofA Securities Evan Seigerman - BMO Capital Markets Operator Good morning and thank you for standing by. Welcome to the AbbVie Third Quarter 2023 Earnings Conference Call.",seekingalpha.com,https://seekingalpha.com/article/4644531-abbvie-inc-abbv-q3-2023-earnings-call-transcript,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-q3-2023-earnings-call-transcript-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 12:02:13,2023-10-27T12:02:13-04:00,2023-10-27,"AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View","AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.",zacks.com,https://www.zacks.com/stock/news/2173886/abbvie-abbv-q3-earnings-beat-shares-down-despite-raised-view,https://images.financialmodelingprep.com/news/abbvie-abbv-q3-earnings-beat-shares-down-despite-raised-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 11:17:45,2023-10-27T11:17:45-04:00,2023-10-27,"Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics","While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2173792/compared-to-estimates-abbvie-abbv-q3-earnings-a-look-at-key-metrics,https://images.financialmodelingprep.com/news/compared-to-estimates-abbvie-abbv-q3-earnings-a-look-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 10:35:58,2023-10-27T10:35:58-04:00,2023-10-27,AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates,"AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $3.66 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2173589/abbvie-abbv-q3-earnings-and-revenues-beat-estimates,https://images.financialmodelingprep.com/news/abbvie-abbv-q3-earnings-and-revenues-beat-estimates-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 10:31:16,2023-10-27T10:31:16-04:00,2023-10-27,Abbvie surprises in 3Q with better than expected Humira sales,"Abbvie (NYSE:ABBV) raised its 2023 profit guidance after a strong quarterly earnings report driven by demand for newer drugs and better-than-expected Humira performance. During 3Q 2023 Abbvie (NYSE:ABBV) posted revenue of $14.2 billion, marking a 7.5% increase from the previous year when it was $13.2 billion and beating the consensus estimate by $0.68 billion.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1031251?SNAPI,https://images.financialmodelingprep.com/news/abbvie-surprises-in-3q-with-better-than-expected-humira-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 09:51:33,2023-10-27T09:51:33-04:00,2023-10-27,"High-yield, deep-value AbbVie fell off the patent cliff and lived","Shares of AbbVie Inc. NYSE: ABBV have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company's results but has done nothing to change its financial health, position, long-term outlook or ability to deliver value for investors.",marketbeat.com,https://www.marketbeat.com/originals/high-yield-deep-value-abbvie-fell-off-the-patent-cliff-and-lived/?utm_source=snapi,https://images.financialmodelingprep.com/news/highyield-deepvalue-abbvie-fell-off-the-patent-cliff-and-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 09:14:37,2023-10-27T09:14:37-04:00,2023-10-27,"AbbVie Stock Slips As Humira Struggles Continue, But Drugmaker Raises Outlook","AbbVie stock dipped Friday after the drugmaker reported better-than-expected third-quarter metrics, as Humira sales continued to dive.",investors.com,https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q3-2023/,https://images.financialmodelingprep.com/news/abbvie-stock-slips-as-humira-struggles-continue-but-drugmaker-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 08:28:00,2023-10-27T08:28:00-04:00,2023-10-27,AbbVie's Humira Sales Sink 36% but Guidance Lifted on Growth From Other Drugs,AbbVie raises earnings guidance for fiscal 2023.,barrons.com,https://www.barrons.com/articles/abbvie-humira-sales-earnings-ad0387bb,https://images.financialmodelingprep.com/news/abbvies-humira-sales-sink-36-but-guidance-lifted-on-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 07:42:42,2023-10-27T07:42:42-04:00,2023-10-27,"AbbVie raises profit forecast after Humira, newer drugs drive results beat","AbbVie on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand for newer drugs.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-profit-forecast-after-humira-newer-drugs-drive-results-beat-2023-10-27/,https://images.financialmodelingprep.com/news/abbvie-raises-profit-forecast-after-humira-newer-drugs-drive-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 07:42:00,2023-10-27T07:42:00-04:00,2023-10-27,AbbVie results beat expectations despite low-cost competition to blockbuster Humira,"AbbVie Inc. ABBV, -0.04% on Friday reported third-quarter sales and profit that topped analyst expectations and raised its full-year earnings outlook, even as its blockbuster autoimmune drug Humira wrestles with new, lower-cost competitors.",marketwatch.com,https://www.marketwatch.com/story/abbvie-results-beat-expectations-despite-low-cost-competition-to-blockbuster-humira-d86fb062,https://images.financialmodelingprep.com/news/abbvie-results-beat-expectations-despite-lowcost-competition-to-blockbuster-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-27 07:38:00,2023-10-27T07:38:00-04:00,2023-10-27,AbbVie Reports Third-Quarter 2023 Financial Results,"Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $13.927 Billion, a Decrease of 6.0 Percent on a Reported Basis and 5.8 Percent on an Operational Basis Third -Quarter Global Net Revenues from the Immunology Portfolio Were $6.783 Billion, a Decrease of 11.3 Percent; Global Humira Net Revenues Were $3.547 Billion; Global Skyrizi Net Revenues Were $2.126 Billion; Global Rinvoq Net Revenues Were $1.110 Billion Third -Quarter Global Net Revenues from the Oncology Portfolio Were $1.512 Billion a Decrease of 8.4 Percent on a Reported Basis, or 8.6 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $908 Million; Global Venclexta Net Revenues Were $590 Million Third -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.043 Billion, an Increase of 22.1 Percent on a Reported Basis, or 22.0 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $748 Million; Global Vraylar Net Revenues Were $751 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $365 Million Third -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.239 Billion, a Decrease of 4.7 Percent on a Reported Basis, or 4.0 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $620 Million; Global Juvederm Net Revenues Were $321 Million Raises 2023 Adjusted Diluted EPS Guidance Range from $10.86 - $11.06 to $11.19 - $11.23, which Includes an Unfavorable Impact of $0.27 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2023 Raises 2024 Adjusted Diluted EPS Guidance Floor from $10.70 to $11.00, which Excludes any Impact Related to Acquired IPR&D and Milestones Expense Announces 2024 Dividend Increase of 4.7 Percent, Beginning with Dividend Payable in February 2024 NORTH CHICAGO, Ill., Oct. 27, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2023-financial-results-301969530.html,https://images.financialmodelingprep.com/news/abbvie-reports-thirdquarter-2023-financial-results-20231027.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-28 03:36:30,2023-10-28T03:36:30-04:00,2023-10-28,"Buy 7 November Dividend Kings, Watch 7 More","""There is only one criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend payout for a minimum of 50 consecutive years.""--Dogs of the Dow. The 49 Dividend Kings screened as of October 25 represented seven of eleven Morningstar Sectors. Broker-targeted top-ten net gains ranged 25.18%-37.56% topped by Target and Gorman-Rupp. By yield, Altria tops all. Top-ten Kingly November yields from ABBV, SWK, FRT, BKH, NWN, CDUAF, MMM, UVV, LEG, & MO averaged 6.12%.",seekingalpha.com,https://seekingalpha.com/article/4644713-buy-7-november-dividend-kings-watch-7-more,https://images.financialmodelingprep.com/news/buy-7-november-dividend-kings-watch-7-more-20231028.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-30 19:07:49,2023-10-30T19:07:49-04:00,2023-10-30,Why AbbVie Stock Was a Winner on Monday,What a difference a single trading day makes -- the shares slumped notably on Friday. This occurred in the wake of the company's latest quarterly earnings report.,fool.com,https://www.fool.com/investing/2023/10/30/why-abbvie-stock-was-a-winner-on-monday/,https://images.financialmodelingprep.com/news/why-abbvie-stock-was-a-winner-on-monday-20231030.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-30 09:38:20,2023-10-30T09:38:20-04:00,2023-10-30,"Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest","Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook:",cnbc.com,https://www.cnbc.com/2023/10/30/here-are-16-stocks-jim-cramer-is-watching-including-microsoft-chevron-southwest.html,https://images.financialmodelingprep.com/news/here-are-16-stocks-jim-cramer-is-watching-including-20231030.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-30 09:15:00,2023-10-30T09:15:00-04:00,2023-10-30,2 No-Brainer Dividend Stocks to Buy This Week,"Value-laden dividend stocks often deliver superior returns compared to other asset classes. AbbVie, a top dividend growth stock, trades at a rock-bottom multiple, despite its above-average yield.",fool.com,https://www.fool.com/investing/2023/10/30/2-no-brainer-dividend-stocks-to-buy-this-week/,https://images.financialmodelingprep.com/news/2-nobrainer-dividend-stocks-to-buy-this-week-20231030.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-30 08:51:07,2023-10-30T08:51:07-04:00,2023-10-30,NEXGEL announces supply agreement with AbbVie,"NEXGEL (NASDAQ:NXGL) announced that its CG Converting and Packaging subsidiary has executed a supply agreement with biopharmaceutical giant AbbVie Inc to be a supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.   The provider of high-water-content hydrogel products said by leveraging its proprietary hydrogel technology, the gel pads will be an important component of the body contouring device.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1031379?SNAPI,https://images.financialmodelingprep.com/news/nexgel-announces-supply-agreement-with-abbvie-20231030.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-30 08:48:03,2023-10-30T08:48:03-04:00,2023-10-30,"Becton, Dickinson And HP Among 13 Companies Announcing Annual Dividend Increases In The First Half Of November","Visa and Exxon Mobil announced dividend increases in October, with Visa increasing its dividend by 15.6% and Exxon Mobil increasing its dividend by 4.4%. Several companies, including AbbVie, American Electric Power, and McDonalds, met or exceeded dividend increase predictions in October. Dividend growth slowed for companies like Amphenol, Black Hills, and Tompkins Financial due to various factors such as the current economic slowdown and flat or lower earnings.",seekingalpha.com,https://seekingalpha.com/article/4644980-becton-dickinson-and-hp-among-13-companies-announcing-annual-dividend-increases-in-the-first-half-of-november,https://images.financialmodelingprep.com/news/becton-dickinson-and-hp-among-13-companies-announcing-annual-20231030.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-31 10:32:33,2023-10-31T10:32:33-04:00,2023-10-31,Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2175275/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock,https://images.financialmodelingprep.com/news/here-is-what-to-know-beyond-why-abbvie-inc-20231031.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-31 10:07:00,2023-10-31T10:07:00-04:00,2023-10-31,Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors,Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolidate its control over that market.,fool.com,https://www.fool.com/investing/2023/10/31/pfizers-coming-for-abbvies-market-share-heres-what/,https://images.financialmodelingprep.com/news/pfizers-coming-for-abbvies-market-share-heres-what-it-20231031.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-31 09:01:24,2023-10-31T09:01:24-04:00,2023-10-31,5 Solid Stocks to Watch That Recently Hiked Dividends,"AbbVie Inc. (ABBV), Exxon Mobil Corporation (XOM), Kontoor Brands, Inc. (KTB), Select Water Solutions, Inc. (WTTR) and Macatawa Bank Corporation (MCBC) recently hiked dividends.",zacks.com,https://www.zacks.com/stock/news/2175228/5-solid-stocks-to-watch-that-recently-hiked-dividends,https://images.financialmodelingprep.com/news/5-solid-stocks-to-watch-that-recently-hiked-dividends-20231031.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-10-31 05:23:00,2023-10-31T05:23:00-04:00,2023-10-31,Is AbbVie Still a Good Dividend Stock to Buy?,AbbVie's best-selling product lost patent-protected market exclusivity in the U.S. this year. Competition with lower-cost biosimilar versions of Humira is expected to shrink earnings for at least a couple of years.,fool.com,https://www.fool.com/investing/2023/10/31/is-abbvie-still-a-good-dividend-stock-to-buy/,https://images.financialmodelingprep.com/news/is-abbvie-still-a-good-dividend-stock-to-buy-20231031.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-01 08:45:00,2023-11-01T08:45:00-04:00,2023-11-01,BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before,"CELEBRATING THE FIFTH ANNUAL BOTOX ® COSMETIC DAY, NEW AND LOYAL ALLĒ MEMBERS BENEFIT FROM MORE EXCITING OFFERS IRVINE, Calif. , Nov. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating the fifth annual BOTOX® Cosmetic Day on Wednesday, November 15.",prnewswire.com,https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-day-is-back-like-never-before-301973724.html,https://images.financialmodelingprep.com/news/botox-cosmetic-onabotulinumtoxina-day-is-back-like-never-before-20231101.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-01 06:07:07,2023-11-01T06:07:07-04:00,2023-11-01,Investor patience tested as pharmaceutical stocks take a tumble,The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.,marketbeat.com,https://www.marketbeat.com/originals/investor-patience-tested-as-pharmaceutical-stocks-take-a-tumble/?utm_source=snapi,https://images.financialmodelingprep.com/news/investor-patience-tested-as-pharmaceutical-stocks-take-a-tumble-20231101.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-02 22:30:04,2023-11-02T22:30:04-04:00,2023-11-02,Meet the Next Trillion-Dollar Companies: Our Top 3 Picks,"The current five trillion-dollar companies listed on U.S. stock exchanges include Apple (NASDAQ: AAPL ), Microsoft (NASDAQ: MSFT ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), Amazon (NASDAQ: AMZN ), and Nvidia (NASD AQ: NVDA ).  These five and two others, Meta Platforms (NASDAQ: META ) and Tesla (NASDAQ: TSLA ), make up “the Magnificent Seven”.",investorplace.com,https://investorplace.com/2023/11/meet-the-next-trillion-dollar-companies-our-top-3-picks/,https://images.financialmodelingprep.com/news/meet-the-next-trilliondollar-companies-our-top-3-picks-20231102.png
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-02 10:34:38,2023-11-02T10:34:38-04:00,2023-11-02,These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,zacks.com,https://www.zacks.com/stock/news/2177085/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar,https://images.financialmodelingprep.com/news/these-2-medical-stocks-could-beat-earnings-why-they-20231102.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-03 05:32:00,2023-11-03T05:32:00-04:00,2023-11-03,Is AbbVie Stock a Buy Now?,"AbbVie's top and bottom lines are struggling, as anticipated. Management thinks this rough patch will be over sometime in 2025.",fool.com,https://www.fool.com/investing/2023/11/03/is-abbvie-stock-a-buy-now/,https://images.financialmodelingprep.com/news/is-abbvie-stock-a-buy-now-20231103.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-04 05:30:00,2023-11-04T05:30:00-04:00,2023-11-04,Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever,"Companies with a track record of dividend increases have shown rewarding shareholders is a priority. If those companies also have strong free cash flow, they may offer you a long future of dividend payments.",fool.com,https://www.fool.com/investing/2023/11/04/want-passive-income-top-dividend-stocks-to-buy/,https://images.financialmodelingprep.com/news/looking-for-a-lifetime-of-passive-income-2-top-20231104.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-05 10:00:00,2023-11-05T10:00:00-05:00,2023-11-05,3 Spectacular High-Yield Dividend Stocks to Buy in November,AbbVie should be poised to return to rapid growth and recently boosted its dividend. Novartis' spin-off of Sandoz doesn't diminish its attractiveness for income investors.,fool.com,https://www.fool.com/investing/2023/11/05/3-spectacular-high-yield-dividend-stocks-to-buy-in/,https://images.financialmodelingprep.com/news/3-spectacular-highyield-dividend-stocks-to-buy-in-november-20231105.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-06 15:32:00,2023-11-06T15:32:00-05:00,2023-11-06,"The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli",Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.,marketwatch.com,https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a,https://images.financialmodelingprep.com/news/the-doctor-lowering-drug-prices-for-1-million-patients-20231106.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-07 20:41:22,2023-11-07T20:41:22-05:00,2023-11-07,3 Dividend Stocks That Are Perfect for Beginning Investors,"While the meme trade phenomenon helped spark interest in the equities sector, passive-income providers generally offer a more solid foundation, thus warranting a closer look at dividend stocks for beginners. To be sure, these aren't the sexiest ideas.",investorplace.com,https://investorplace.com/2023/11/3-dividend-stocks-that-are-perfect-for-beginning-investors/,https://images.financialmodelingprep.com/news/3-dividend-stocks-that-are-perfect-for-beginning-investors-20231107.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-07 06:12:57,2023-11-07T06:12:57-05:00,2023-11-07,"Guidance leads the market for these stocks; 1 raises, 1 lowers","Because earnings guidance is a company's best effort to forecast its earnings, it is a leading cause of share price movement. However, simply raising or lowering guidance is not enough to move a market.",marketbeat.com,https://www.marketbeat.com/originals/guidance-leads-the-market-for-these-stocks-1-raises-1-lowers/?utm_source=snapi,https://images.financialmodelingprep.com/news/guidance-leads-the-market-for-these-stocks-1-raises-20231107.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-08 11:27:40,2023-11-08T11:27:40-05:00,2023-11-08,4 Dividend Aristocrats Signal Buys In November As 6 Await,"""Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. ""-- Kiplinger.com/Investing. 66 Aristocrats, screened as of November 6, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 22.29%-34.44% topped-by O & WBA.",seekingalpha.com,https://seekingalpha.com/article/4649136-4-dividend-aristocrats-signal-buys-in-november-as-6-await,https://images.financialmodelingprep.com/news/4-dividend-aristocrats-signal-buys-in-november-as-6-20231108.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-08 08:45:00,2023-11-08T08:45:00-05:00,2023-11-08,"Natrelle® Unveils New ""For Every BODY"" Campaign","Refreshed Look Spotlights Most Diverse Breast Implant Portfolio for a Customized Look IRVINE, Calif. , Nov. 8, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), embraces the immensely personal choice that patients experience when choosing breast surgery.",prnewswire.com,https://www.prnewswire.com/news-releases/natrelle-unveils-new-for-every-body-campaign-301980875.html,https://images.financialmodelingprep.com/news/natrelle-unveils-new-for-every-body-campaign-20231108.jpg
ABBV,2023-10-27,2023-10-13,2023-11-10,ABBV,,2023-11-08 07:18:00,2023-11-08T07:18:00-05:00,2023-11-08,Grab these 2 funds with rich 11%-12% yields while you can,With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.,marketwatch.com,https://www.marketwatch.com/story/grab-these-2-funds-with-rich-11-12-yields-while-you-can-f2856fb2,https://images.financialmodelingprep.com/news/grab-these-2-funds-with-rich-1112-yields-while-20231108.jpg
